Real-world systemic sequential therapy with regorafenib for recurrent hepatocellular carcinoma: analysis of 93 cases from a single center

被引：0
|
作者：
Qingwei Zhu
Wei Rao
Junyu Huo
Zixiang Li
Song Wang
Wensheng Qiu
Ge Guan
Yang Xin
Ning Fan
Jinzhen Cai
Liqun Wu
机构：
[1] The Affiliated Hospital of Qingdao University,Liver Disease Center
[2] The Affiliated Hospital of Qingdao University,Department of Interventional Medicine Cancer Hospital
[3] Tumor Hospital,undefined
[4] The Affiliated Hospital of Qingdao University,undefined
来源：
BMC Gastroenterology | / 23卷
关键词：
Hepatocellular carcinoma; Regorafenib; Combination therapy; Real-world research;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Single center real-world treatment and outcomes in patients with hepatocellular carcinoma receiving immunotherapy.
    Patel, Ronak
    Algaze, Sandra
    Habib, Diane
    Iqbal, Syma
    Chiu, Victor Yundeh
    El-Khoueiry, Anthony B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16134 - E16134
  • [22] Real-world experience of atezolizumab and bevacizumab for treatment of advanced hepatocellular carcinoma in a single tertiary center
    Raharjo, C. V.
    Joseph, R.
    Stratton, E.
    Levy, M.
    Prakoso, E.
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 22 - 22
  • [23] Single-center real-world treatment and outcomes in patients with hepatocellular carcinoma receiving immunotherapy
    Habib, Diane
    Patel, Ronak
    Algaze, Sandra
    Iqbal, Syma
    Chiu, Victor Yundeh
    El-Khoueiry, Anthony B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [24] Regorafenib with immunotherapy versus regorafenib alone as second-line treatment for hepatocellular carcinoma: A multicenter real-world study
    Qiao, Liang
    He, Wei
    Wang, Guoying
    Chen, Huanwei
    Huang, Fuxi
    Zhang, Bo
    Qiu, Yuxiong
    Liu, Shaoru
    Huang, Zhenkun
    Yuan, Yichuan
    Qiu, Jiliang
    Yuan, Yunfei
    Li, Binkui
    [J]. CANCER MEDICINE, 2024, 13 (09):
  • [25] Regorafenib Versus Nivolumab After Sorafenib Failure: Real-World Data in Patients With Hepatocellular Carcinoma
    Choi, Won-Mook
    Choi, Jonggi
    Lee, Danbi
    Shim, Ju Hyun
    Lim, Young-Suk
    Lee, Han Chu
    Chung, Young-Hwa
    Lee, Young-Sang
    Park, Sook Ryun
    Ryu, Min-Hee
    Ryoo, Baek-Yeol
    Lee, So Jung
    Kim, Kang Mo
    [J]. HEPATOLOGY COMMUNICATIONS, 2020, 4 (07) : 1073 - 1086
  • [26] Comparative efficacy of systemic sequential regorafenib after TACE combined with first-line targeted drugs (donafenib, sorafenib, or lenvatinib) after treatment failure for advanced hepatocellular carcinoma: A retrospective, single-center, real-world study
    Wei, Ning
    Lu, Dong
    Zhou, Chunze
    Cheng, Delei
    Zhang, Zhengfeng
    Zhang, Xingming
    Xiao, Jingkun
    Lv, Weifu
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] Regorafenib versus nivolumab after sorafenib failure: real-world data in patients with hepatocellular carcinoma
    Choi, Won-Mook
    Choi, Jonggi
    Shim, Ju Hyun
    Lim, Young-Suk
    Lee, Han Chu
    Kim, Kang Mo
    [J]. JOURNAL OF HEPATOLOGY, 2020, 73 : S39 - S39
  • [28] Analysis of real-world implementation of systemic treatment in biliary tract cancer - a single center analysis
    Zhang, D.
    Dorman, K.
    Haas, M.
    Westphalen, C. B.
    Jens, W.
    Mayerle, J.
    Heinemann, V.
    Boeck, S.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 129 - 130
  • [29] Systemic therapy with or without transcatheter intra-arterial therapies for unresectable hepatocellular carcinoma: a real-world, multi-center study
    Pan, Yangxun
    Zhu, Xiaodong
    Liu, Jianwei
    Zhong, Jianhong
    Zhang, Wei
    Shen, Shunli
    Jin, Renan
    Liu, Hongzhi
    Ye, Feng
    Hu, Kuan
    Xu, Da
    Zhang, Yu
    Chen, Zhong
    Xing, Baocai
    Zhou, Ledu
    Chen, Yongjun
    Zeng, Yongyi
    Liang, Xiao
    Kuang, Ming
    Song, Tianqiang
    Xiang, Bangde
    Wang, Kui
    Sun, Huichuan
    Xu, Li
    [J]. FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [30] Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma
    Hong, Young Mi
    Yoon, K. T.
    Cho, Mong
    [J]. BMC CANCER, 2021, 21 (01)
12345